MedTrace Logo

Apatinib in Advanced Non-squamous，NSCLC

NCT03376191 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2017-12-18

No results posted yet for this study

Summary

To explore the efficacy and safety of apatinib in non-squamous non-small cell lung cancer in the real-world.

Conditions

  • Non-squamous Non-Small Cell Lung Cancer

Interventions

DRUG

apatinib

Clinicians chose the initial dose of apatinib according to the patient's physical condition. Besides the clinicians adjusted the dose according to the patient's tolerance during the medication.The dosage was demanded not higher than 750 milligram (mg) per day. The patients received apatinib continuously, 28 days for a period, until intolerance, no longer getting benefits or patient wanted stop.

Sponsors & Collaborators

  • The Second Affiliated Hospital of Harbin Medical University

    collaborator OTHER

  • Peking University Third Hospital

    collaborator OTHER

  • Peking University First Hospital

    collaborator OTHER

  • Jian Fang

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-01
Primary Completion
2019-04-01
Completion
2019-10-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03376191 on ClinicalTrials.gov